NDLI: LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer

Content Provider	Springer Nature : BioMed Central
Author	Dey, Goutam Bharti, Rashmi Braley, Chad Alluri, Ravi Esakov, Emily Crean-Tate, Katie McCrae, Keith Joehlin-Price, Amy Rose, Peter G. Lathia, Justin Gong, Zihua Reizes, Ofer
Abstract	Poly-ADP Ribose Polymerase (PARP) targeted therapy is clinically approved for the treatment of homologous recombination (HR) repair deficient tumors. The remarkable success of this therapy in the treatment of HR repair deficient cancers has not translated to HR-proficient cancers. Our studies identify the novel role of non-receptor lymphocyte-specific protein tyrosine kinase (LCK) in the regulation of HR repair in endometrioid epithelial ovarian cancer (eEOC) model. We show that DNA damage leads to direct interaction of LCK with the HR repair proteins RAD51 and BRCA1 in a kinase dependent manner RAD51 and BRCA1 stabilization. LCK expression is induced and activated in the nucleus in response to DNA damage insult. Disruption of LCK expression attenuates RAD51, BRCA1, and BRCA2 protein expression by hampering there stability and results in inhibition of HR-mediated DNA repair including suppression of RAD51 foci formation, and augmentation of γH2AX foci formation. In contrast LCK overexpression leads to increased RAD51 and BRCA1 expression with a concomitant increase in HR DNA damage repair. Importantly, attenuation of LCK sensitizes HR-proficient eEOC cells to PARP inhibitor in cells and pre-clinical mouse studies. Collectively, our findings identify a novel therapeutic strategy to expand the utility of PARP targeted therapy in HR proficient ovarian cancer. Graphical Abstract
Related Links	https://ovarianresearch.biomedcentral.com/counter/pdf/10.1186/s13048-023-01194-2.pdf
Ending Page	19
Page Count	19
Starting Page	1
File Format	HTM / HTML
ISSN	17572215
DOI	10.1186/s13048-023-01194-2
Journal	Journal of Ovarian Research
Issue Number	1
Volume Number	16
Language	English
Publisher	BioMed Central
Publisher Date	2023-06-27
Access Restriction	Open
Subject Keyword	Gynecology Reproductive Medicine
Content Type	Text
Resource Type	Article
Subject	Oncology Obstetrics and Gynecology
Journal Impact Factor	3.8/2023
5-Year Journal Impact Factor	4.2/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair

DNA damage repair in ovarian cancer: unlocking the heterogeneity

Exosomes secreted by chemoresistant ovarian cancer cells promote angiogenesis

Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors

Heterozygous FMN2 missense variant found in a family case of premature ovarian insufficiency

Targeting mitochondrial metabolism with CPI-613 in chemoresistant ovarian tumors

BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Role of chemotherapy in the future treatment of ovarian cancer

LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer

Similar Documents

Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair

DNA damage repair in ovarian cancer: unlocking the heterogeneity

Exosomes secreted by chemoresistant ovarian cancer cells promote angiogenesis

Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors

Heterozygous FMN2 missense variant found in a family case of premature ovarian insufficiency

Targeting mitochondrial metabolism with CPI-613 in chemoresistant ovarian tumors

BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Role of chemotherapy in the future treatment of ovarian cancer

LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer